Mechanistic findings suggest that IDH mutant glioma cells can acquire resistance to NK cells by inhibiting ULBP1 and ULBP3 expression through NKG2D ligands, and decitabine‐mediated hypomethylation restores ULBP1 and ULBP3 expression in IDH mutant glioma cells, which may be a useful target for immune monitoring in patients with IDH mutant diffuse glioma.75 Here, ULBP3 is linked to central nervous system cancer.